Katonga
03 Apr 2018
Results I understood they were due to-day,but obviously not.So when are they due.
QHSS
28 Mar 2018
Possible Offer for Shire by Takeda Any views anyone on what might BTG be worth in Share Price Value in the current climate in a Take Over scenario?And who are the likely candidates be?
Ambiorix1
16 Feb 2018
Something to think about ... 16/02/2018(reworked from an T. Straton article)Johnson & Johnson just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer. J&J’s new drug apalutamide won FDA approval months ahead of its scheduled decision date. It’s now ready to scoop up market share before its rivals win a new, similar indication for their treatment, Xtandi.Now known as Erleada, apalutamide is the first therapy to win approval for nonmetastatic prostate cancer, the FDA said, and the first to get a green light based on metastasis-free survival numbers. It’s also J&J’s follow-up to its blockbuster prostate cancer drug Zytiga, which scored a few approval firsts of its own but now faces an earlier-than-expected battle against generics later this year.Zytiga royalties for BTG on their way down from now on...?Ambiorix.
up protherics
05 Feb 2018
pathetic One consolation is that there are now some bargains looming else where. INMO this is not one of them.May be to compensate long term holders they could start paying a dividend. 20p to start would give some value back to holders .This now seems to be a stock to constantly short rather than invest.. INMO they have bought this on themselves with their consistant ineptnus of late .
d gaser
03 Feb 2018
price against the DOW Jones being down 640 points Pouloverd the DOW fell 640points or 2.50% and every other market fell as well by as much if not more . Pharmaceutical shares are also out of favour in the US at the moment , as Trump has said he wants the cost of drugs to fall, but as BTG, seem to prefer the US market to any other, it means BTG can't lay off any cuts to our margins to other countries .BE HAPPYDAVE
pauloverdi
02 Feb 2018
Share price Can you Adam & Eve the non stop vagaries of btg share price !! No news and weak sales !We went high this week and now it drops like a stone!! Why ?? It seems to me that the mm's see that mostly we are not selling out so they keep playing with the price to create movement!!D Gasser your take has been invaluable so what is your opinion please ?Kind regardsPaulo
d gaser
27 Jan 2018
Re: Pound up above pre dollar Brexit price . Sorry posted wrong post ,please see correct one below .Sorry Dave Hi Like a dog with two tails .I was not making a political point ,but I was trying to point out that BTG seem to prefer operating in the USA only ,rather than release our products into Europe or the far east ,and that leaves us open to trying to predict our main markets long term currency value , and as we all know that is very difficult to-do . last year for instance BTG hedged the wrong way against the dollar, and lost us valuable profits .This year they reversed their view and hedged against a stronger dollar as the Brexit annalists were predicting, the dollar would continue to strengthen, due to Brexit and tax cuts and infrastructure spending in the USA , but now we find our self's on the wrong side of that hedge, as the dollar is declining against the pound, and the pound is now re- cooping much of the loses sustained after the initial Brexit announcement thanks to the increased manufacturing and service sector sales to the rest of the world . To me BTG are now missing out on sales to those markets by concentrating on the north American market only and are now being held hostage to the dollar .Just looking at the accounts for 2017, on page 125, it states that BTG total sales came in at £570.5m ,and that sales to the USA came in at £513.7m, yet in Europe, BTG only managed £42.1 m, and for the rest the world a poorly 15.7m. I for one can not understand those figures, or why, BTG won't expand our market base for certain products to the rest of the world ,as that could help BTG with the problem of guessing which way to hedge the dollar ,and would also give this company instant growth potential .At the moment the UK don't have a free trade deal with the USA or Canada, yet BTG have no problems trading there , on the other hand we do have a free trade deal in Europe, yet BTG, don't seem to want to trade there, in a big way, why ?, and why do, BTG concentrate on America and Canada, as it appears, they don't find it difficult exporting our products to both countries, even though the UK don't have a free trade deal in either country ,strange that don't you think ..BE HAPPYDAVE
d gaser
27 Jan 2018
Re: Pound up above pre Brexit price . Like a dog with two tails .I was not making a political point ,but I was trying to point out that BTG seem to prefer operating in the USA only ,rather than release our products into Europe or the far east ,and that leaves us open to trying to predict our main markets long term currency value , and as we all know that is very difficult to-do . last year for instance BTG hedged the wrong way against the dollar, and lost us valuable profits .This year they reversed their view and hedged against a stronger dollar as the Brexit annalists were predicting, the dollar would continue to strengthen, due to Brexit and tax cuts ,and infrastructure spending in the USA , but now we find our self's on the wrong side of that hedge as the dollar is declining against the pound and the pound is re- cooping much of the loses thanks to increased manufacturing and service sector sales in the rest of the world. To me BTG are missing out on sales by just concentrating on the USA ,and are being held hostage to the dollar .Just looking at the accounts for 2017, on page 125, it states that BTG total sales came in at £570.5m ,and that sales to the came in at £513.7m, yet in Europe BTG only managed £42.1 m, and for the rest the world a poorly 15.7m. I for one can not understand those figures, or why BTG won't expand our market base for certain products as that could help BTG with the problem of guessing which way to hedge the dollar ,and would also give this company instant growth potential . At the moment we don't have a free trade deal with the USA or Canada but BTG have no problems trading there ,yet we do have a free trade deal in Europe, yet BTG don't appear to want to trade there in a big way, why ?, and why do BTG concentrate on America and Canada, as it appears they don't find it difficult exporting to both countries, even though the UK don't have a free trade deal in either country strange that ..BE HAPPYDAVE
Like a dog with two
25 Jan 2018
Re: Pound up above pre Brexit price . For a bit of balance...Sterling is still a long way down on the Euro since the Brexit vote.Sterling is doing well against the Dollar, more due to Dollar weakness than Sterling strength.The BBC has today reported on rate against the Dollar hitting a post Brexit vote high.There has been no Brexit yet, only a vote and initial negotiation, whether Brexit is positive, negative or just different for the UK is yet to be seen, and might never be clear due to other factors having a greater effect.
d gaser
24 Jan 2018
Pound up above pre Brexit price . If any body is wondering why the price has fallen today ,it's because the pound has again strengthened against the dollar, and is now above its pre Brexit price .Unfortunately we were told, this wouldn't happen if Brexit went ahead, well it has, so much for those city analyst's , who think they know what's going on in the world and I bet the BBC don't broadcast this event .This will of course impact on BTG profits in the USA , which of course is our main market by choice ,but is now proving a liability when it comes to of setting the Pound dollar exchange rates long term .Be Happy Dav
d gaser
19 Jan 2018
Re: Northwestern Uni Adopts TheraSpher a... As far as I know is that this university Hospital have been trialling the product and as I understand it they concluded it gives greater life expectancy than the present treatments, and because of that they will use it as a first line medicine ,cost will obviously come into that equation but as it can be done in a day, as a day patient ,that means less visits to the hospital, and it’s less invasive than the present treatments, www.cancer.org/cancer/liver-cancer/treating/embolization-therapy.htmlIf you click on to the above web site I think most of your questions can be answered there ,regarding how many people it could help ,however, as far as I know, this product has not yet received FDA clearance. (see the BTG web site for clarification , www.btgplc.com/media/press-releases/institutional-decision-to-adopt-y90-tare-with-therasphere-as-first-line-treatment-for-hcc/ you will see there it states that the DC Bead® is not currently cleared by the FDA for sale or distribution in the USA ,but it does have clearance in China, EU, Japan, Republic of Korea ,and can be used in the US , under certain rules see [link] . It might be that this universerty hospital has some thing to do with getting FDA clearance. how ever the fact that this institution has adopted the Y90 transarterial radioembolisation (TARE) with TheraSphere® is a big step forward, as TheraSphere® is also approved for the treatment of hepatic neoplasia in the US , and TheraSphere® it self has all ready been approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant .The fact that Northweston and it’s hospital have decided to recommend TheraSphere® with Y90 as a first-line transarterial LRT for its patients with HCC means a lot more people will be given it . The other thing is the American Cancer society talk about the process favourable in their documents, I would suggest that others will now follow suit in due course, and according to the Centre for Disease Control and Protection (CDC) each year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the United States alone. But let’s say only 25% of those patients where to be treated with our product as a first line treatment, then BTG would be looking at a worldwide block buster product, worth billions of pounds. It’s also worth looking at www.cancer.net/cancer-types/liver-cancer/statistics BE HAPPYPDYHDave 
JefH
19 Jan 2018
Re: Northwestern Uni Adopts TheraSpher as first line treatment Hi DG, thanks for that. Any idea how important this is in the wider adoption of Theraspere as a treatment?
pauloverdi
19 Jan 2018
Zytiga administrative court invalidated a Johnson & Johnson (JNJ.N) patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc (BTG.L).The Patent Trial and Appeal Board said a Johnson & Johnson patent describing a method of administering Zytiga should not have been granted because the process it described was obvious.Wednesday's ruling was a victory for U.S. generic drug company Argentum Pharmaceuticals LLC, which had asked the board to invalidate the patent in the hope of being able to bring its own version to market.Johnson & Johnson said it strongly disagreed with the decision and might ask a federal appeals court to reverse it.Argentum did not immediately return a request for comment.The patent is due to expire in 2027. Argentum and other generic drug makers have been blocked from launching their own versions of the cancer drug until its expiration date.Zytiga generated nearly $2.3 billion (£1.66 billion) in sales for Johnson & Johnson in 2016.The drug is also a money-spinner for healthcare group BTG, which earns royalties on sales of a medicine that was originally developed by cancer researchers in Britain. BTG shares fell 5 percent on Thursday on fears for this revenue stream.A BTG spokesman said its previous guidance on Zytiga royalties was unchanged and the group maintained that the earliest likely U.S. generic entry would be October 2018.
up protherics
18 Jan 2018
Re: Share price pauloverdiIt is down to the patent being lost on zytiga in the states..Johnson and Johnson are going to appeal .. I just hope BTG have not agreed to pay towards legal fees, but who knows with them
pauloverdi
18 Jan 2018
Share price Hey we know we're all bored and fed up with the stagnant progression of the company but I'm not aware of any news that dictates the large fall in the share price today !!!Any ideas ???Paulo
